TY - JOUR
T1 - Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation
T2 - Macrophage-targeted steroid therapy
AU - Nishiwaki, Satoshi
AU - Saito, Shigeki
AU - Goto, Tatsunori
AU - Miyamura, Koichi
AU - Nakayama, Takayuki
AU - Kato, Tomonori
AU - Koyama, Daisuke
AU - Murata, Makoto
AU - Mizuno, Hiroki
AU - Yokohata, Emi
AU - Matsumoto, Kimikazu
AU - Nishida, Tetsuya
AU - Imahashi, Nobuhiko
AU - Kubota, Naomi
AU - Ito, Masafumi
AU - Sugimoto, Kyoko
AU - Seto, Aika
AU - Ozawa, Yukiyasu
AU - Kamoshita, Sonoko
AU - Naoe, Tomoki
N1 - Funding Information:
Acknowledgments This study was supported in part by a grant from the Japan Society for the Promotion of Science to S.N., and in part by a Japanese Grant-in-Aid for Scientific Research [(C) 2059 1118] to T. Nakayama.
PY - 2012/4
Y1 - 2012/4
N2 - Hemophagocytic syndrome (HPS) induced by uncontrolled macrophage activation and subsequent graft failure is a frequent and prominent complication after allogeneic stem cell transplantation (allo-SCT), a cause of severe morbidity and death, and a therapeutic challenge. Liposomeincorporated dexamethasone, dexamethasone palmitate (DP), shows greater efficacy against macrophages as compared to dexamethasone sodium phosphate (DSP). Based on our findings that DP achieves significantly larger decrease than DSP on the viability of primary human macrophages compared in vitro, we tested the effects of DP in patients with HPS. A decrease in number of macrophages in the bone marrow and prevention of engraftment failure were observed in all patients without any severe complications. In conclusion, these data provide a rationale for testing DP as a firstline treatment for patients with HPS after allo-SCT.
AB - Hemophagocytic syndrome (HPS) induced by uncontrolled macrophage activation and subsequent graft failure is a frequent and prominent complication after allogeneic stem cell transplantation (allo-SCT), a cause of severe morbidity and death, and a therapeutic challenge. Liposomeincorporated dexamethasone, dexamethasone palmitate (DP), shows greater efficacy against macrophages as compared to dexamethasone sodium phosphate (DSP). Based on our findings that DP achieves significantly larger decrease than DSP on the viability of primary human macrophages compared in vitro, we tested the effects of DP in patients with HPS. A decrease in number of macrophages in the bone marrow and prevention of engraftment failure were observed in all patients without any severe complications. In conclusion, these data provide a rationale for testing DP as a firstline treatment for patients with HPS after allo-SCT.
UR - http://www.scopus.com/inward/record.url?scp=84862885421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862885421&partnerID=8YFLogxK
U2 - 10.1007/s12185-012-1023-z
DO - 10.1007/s12185-012-1023-z
M3 - Article
C2 - 22351164
AN - SCOPUS:84862885421
SN - 0925-5710
VL - 95
SP - 428
EP - 433
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 4
ER -